세계 삼출성 노인성 황반변성 시장은 노인 인구 증가, 이 질환에 대한 인식 개선, 치료법의 발전으로 인해 견조한 성장세를 보이고 있습니다.
습성 노인황반변성의 주요 치료법으로는 항VEGF(혈관내피성장인자) 치료, 광역학 치료(PDT), 레이저 수술 등이 있으며, 항VEGF 약물이 질환의 진행을 억제하거나 지연시키는 효과가 입증되어 시장 점유율의 가장 큰 부분을 차지하고 있습니다.
이 시장의 가장 중요한 성장 요인은 전 세계적인 고령화입니다. 사람들의 수명이 길어짐에 따라 습성 노인황반변성을 포함한 노화 관련 안질환의 발병률도 증가합니다. 황반변성은 특히 65세 이상에서 많이 발생하는데, 선진국을 중심으로 노인 인구가 증가함에 따라 삼출성 황반변성 환자도 증가하고 있습니다. UN은 80세 이상 인구가 2019년 1억 4,300만 명에서 2050년 4억 2,600만 명으로 증가할 것으로 예측하고 있으며, 이에 따라 습성 노인황반변성 치료를 필요로 하는 환자층도 확대될 것으로 예상하고 있습니다.
빛간섭단층촬영(OCT)과 안저사진과 같은 기술의 발전으로 습성 노인황반변성을 조기에 발견할 수 있는 능력이 크게 향상되었습니다. 조기 진단을 통해 적시에 개입할 수 있어 질병의 진행을 늦추고 환자의 예후를 개선할 수 있습니다. 이러한 첨단 진단 기기의 클리닉과 병원에서의 채택이 증가함에 따라 항 VEGF 치료 및 기타 치료가 필요한 환자를 식별할 수 있게 되어 시장 성장을 가속하고 있습니다.
습성 노인황반변성 시장이 계속 진화하고 있는 가운데, 장시간 작용하는 치료제 개발, AI를 통한 조기 발견 등 첨단 진단 기술 도입, 맞춤형 의료에 대한 관심 증가 등 새로운 트렌드가 향후 시장 방향을 형성할 것으로 전망됩니다. 특히 의료 인프라가 부족한 지역에서 보다 저렴하고 효과적이며 접근하기 쉬운 치료법에 대한 수요가 증가하고 있어 시장 확대를 위한 큰 기회를 창출할 것으로 기대됩니다.
세계의 습성 노인황반변성 시장을 조사했으며, 주요 동향, 시장 영향요인 분석, 법 및 규제 환경, 임상시험 동향, 시장 규모 추이 및 예측, 각종 부문별/지역별/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
Global Wet Age-Related Macular Degeneration Market, Analysis and Forecast: 2025-2035
Wet age-related macular degeneration is a progressive eye disease that is a leading cause of vision loss in individuals over the age of 50. It occurs when abnormal blood vessels grow under the retina, leaking fluid and causing damage to the macula, which is responsible for central vision. The condition severely affects the ability to read, recognize faces, and perform other tasks that require sharp vision. Wet age-related macular degeneration represents a major challenge for healthcare systems globally, as it significantly impacts the quality of life and imposes a high burden on individuals and economies.
The global wet age-related macular degeneration market is experiencing robust growth, driven by an aging population, increasing awareness about the condition, and advancements in treatment options. Key therapeutic approaches for wet age-related macular degeneration include anti-VEGF (vascular endothelial growth factor) therapies, photodynamic therapy, and laser surgeries, with the anti-VEGF drugs holding the largest market share due to their proven efficacy in halting or slowing disease progression. Furthermore, emerging treatments, including cell and gene therapy and stem cell therapy, are gaining attention as potential future solutions.
The most significant driver for the wet age-related macular degeneration market is the aging global population. As people live longer, the incidence of age-related eye conditions, including wet age-related macular degeneration, increases. Age-related macular degeneration is most common in individuals aged 65 and older, and as the world's elderly population continues to grow, particularly in developed nations, the number of wet age-related macular degeneration cases rises. The UN projects that the number of people aged 80 and older will increase from 143 million in 2019 to 426 million by 2050, leading to a larger patient pool for wet age-related macular degeneration treatments.
Technologies such as optical coherence tomography (OCT) and fundus photography have greatly enhanced the ability to detect wet age-related macular degeneration at an early stage. Early diagnosis allows for timely intervention, helping to slow disease progression and improve patient outcomes. The adoption of advanced diagnostic tools in clinics and hospitals is driving market growth by enabling healthcare providers to identify patients who would benefit from anti-VEGF therapies or other treatments.
The wet age-related macular degeneration market is indeed growing due to increasing awareness, technological advances in treatments, and an aging global population. However, the combination of high treatment costs, side effects, limited access to care, and the ongoing challenge of offering curative treatments are significant factors restricting the market's potential. Companies in the sector need to focus on reducing the cost of treatment, improving patient adherence, and advancing research to provide long-term and potentially curative therapies for Wet AMD. Addressing these challenges will be key to unlocking the market's full growth potential.
Some of the major players in the global wet age-related macular degeneration market, such as Regeneron Pharmaceuticals Inc., Kubota Pharmaceutical Holdings Co. Ltd, and Adverum Biotechnologies Inc., are continuously innovating to improve the effectiveness and comfort of wet age-related macular degeneration products. These companies are investing heavily in research and development to introduce new, technologically advanced solutions that cater to market growth. With a strong emphasis on user-friendly and environmentally sustainable products, these companies are shaping the future of wet age-related macular degeneration while enhancing their market positions globally.
The competitive landscape of the global wet age-related macular degeneration market is diverse, with numerous players across different regions offering a wide range of products. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the wet age-related macular degeneration market will continue to evolve, fostering new opportunities for both established and emerging companies.
Market Segmentation:
Segmentation 1: by Treatment Type
Segmentation 2: by Region
As the wet age-related macular degeneration market continues to evolve, emerging trends such as the development of long-acting therapies, the integration of advanced diagnostic technologies like artificial intelligence (AI) for early detection, and the increasing focus on personalized medicine will shape its future trajectory. The growing demand for more affordable, effective, and accessible wet age-related macular degeneration treatments, particularly in underserved regions with limited healthcare infrastructure, will create significant opportunities for market expansion.
In conclusion, the global wet age-related macular degeneration market is on track for continued growth, driven by the aging population, increasing awareness of wet age-related macular degeneration, and the development of more effective and comfortable solutions. The ongoing advancements in product technology and the expansion of care options will continue to shape the market's future. As demand for wet age-related macular degeneration solutions rises, both global and regional players will play a key role in meeting the needs of individuals and healthcare systems alike, improving the quality of life for people living with incontinence.
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note